Advertisement

FDA Approval of Pemigatinib and Update From the STAMPEDE Trial


On this episode, we’re covering the U.S. Food and Drug Administration (FDA) approval of pemigatinib for patients with myeloid or lymphoid neoplasms and an FGFR1 rearrangement. We’ll also discuss a long-term update from the STAMPEDE trial of radiotherapy in prostate cancer.




Advertisement
Advertisement

Advertisement




Advertisement